Reviewer’s report

Title: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

Version: 1 Date: 5 February 2013

Reviewer: Shalini Kulasingam

Reviewer’s report:

Major compulsory revisions:
This is a well written, clearly designed analysis to examine the impact of first line treatment with pazopanib compared to sunitinib for advanced RCC.
The analysis rests on differences in gains in life-expectancy, costs for treatment and side-effects and quality of life.
The two sources cited for this analysis are from two different studies. However, since submission of this manuscript, data from the COMPARZ trial (‘COMParing the efficacy, sAfety and toleRability of paZopanib versus sunitinib’ which is funded by GSK (the company which the authors work for) have been published. This trial provides data that directly compares the two drugs modeled, including data on side effects, that would improve the validity and relevance of this study. These data should be included and the modeling work updated accordingly and reconsidered for publication

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no financial competing interests.